Corrigendum: An error in reference 77 was corrected. The original reference was incorrect, and the correct one is Schrier, R.W., and Wang, W. 2004. Acute renal failure and sepsis. N. Engl. J. Med. 351:159–169. Erratum: In the Results section of the manuscript, an error was introduced. The correct sentence is: In line ADAM10-mo × APP [V717], Aβ40 and Aβ42 were reduced by 49% and 20%, and in line ADAM10-hi × APP [V717], by 39% and 29%, respectively. Erratum: During the preparation of the manuscript for publication, an error was introduced into the panel labels of Figure 1. The correct figure is provided. The figure shows the expression of IDO in human and murine TDLNs. (A) Sentinel (first draining) LN from patients with breast carcinoma (left, ×100) and malignant melanoma (right, ×400), showing an abnormal infiltration of IDO+ cells (red chromogen). (B) Kaplan-Meier survival plot of 40 patients with malignant melanoma, stratified into those with an abnormal accumulation of IDO+ cells in the sentinel LN (+IDO), versus a normal (negative) pattern. (C) Expression of IDO in murine B16F10 melanoma. Left: Draining inguinal LN from a mouse with a B16F10 tumor, day 12, stained for IDO (red, ×100). Middle: Contralateral inguinal LN from the same animal as at left, stained for IDO (red, ×100). Right: High-power view of IDO+ cells shown in the left panel (×1,000). Controls for staining (anti-IDO antibody-neutralized with the immunizing peptide) showed a negative pattern similar to that seen in the contralateral LN (not shown). (D) Draining and contralateral LNs from a mouse with B78H1-GM-CSF tumor, day 12, stained for IDO (red, both ×200).Corrigendum: An error in reference 77 was corrected. The original reference was incorrect, and the correct one is Schrier, R.W., and Wang, W. 2004. Acute renal failure and sepsis. N. Engl. J. Med. 351:159–169. Erratum: In the Results section of the manuscript, an error was introduced. The correct sentence is: In line ADAM10-mo × APP [V717], Aβ40 and Aβ42 were reduced by 49% and 20%, and in line ADAM10-hi × APP [V717], by 39% and 29%, respectively. Erratum: During the preparation of the manuscript for publication, an error was introduced into the panel labels of Figure 1. The correct figure is provided. The figure shows the expression of IDO in human and murine TDLNs. (A) Sentinel (first draining) LN from patients with breast carcinoma (left, ×100) and malignant melanoma (right, ×400), showing an abnormal infiltration of IDO+ cells (red chromogen). (B) Kaplan-Meier survival plot of 40 patients with malignant melanoma, stratified into those with an abnormal accumulation of IDO+ cells in the sentinel LN (+IDO), versus a normal (negative) pattern. (C) Expression of IDO in murine B16F10 melanoma. Left: Draining inguinal LN from a mouse with a B16F10 tumor, day 12, stained for IDO (red, ×100). Middle: Contralateral inguinal LN from the same animal as at left, stained for IDO (red, ×100). Right: High-power view of IDO+ cells shown in the left panel (×1,000). Controls for staining (anti-IDO antibody-neutralized with the immunizing peptide) showed a negative pattern similar to that seen in the contralateral LN (not shown). (D) Draining and contralateral LNs from a mouse with B78H1-GM-CSF tumor, day 12, stained for IDO (red, both ×200).